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Abstract. 
 
While P-glycoprotein (Pgp) is the most stud-
ied protein involved in resistance to anti-cancer drugs, 
its mechanism of action is still under debate. Studies of 
Pgp have used cell lines selected with chemotherapeu-
tics which may have developed many mechanisms of re-
sistance. To eliminate the confounding effects of drug 
selection on understanding the action of Pgp, we stud-
ied cells transiently transfected with a Pgp-green ﬂuo-
rescent protein (GFP) fusion protein. This method gen-
erated a mixed population of unselected cells with a 
wide range of Pgp-GFP expression levels and allowed 
simultaneous measurements of Pgp level and drug
accumulation in living cells. The results showed that 
Pgp-GFP expression was inversely related to the accu-
mulation of chemotherapeutic drugs. The reduction in 
drug concentration was reversed by agents that block 
multiple drug resistance (MDR) and by the UIC2
anti-Pgp antibody. Quantitative analysis revealed an
inverse linear relationship between the ﬂuorescence of 
Pgp-GFP and MDR dyes. This suggests that Pgp levels 
alone limit drug accumulation by active efﬂux; cooper-
ativity between enzyme, substrate, or inhibitor mole-
cules is not required. Additionally, Pgp-GFP expression 
did not change cellular pH. Our study demonstrates the 
value of using GFP fusion proteins for quantitative bio-
chemistry in living cells.
Key words: multiple drug resistance • green ﬂuores-
cent protein • ATP cassette-binding proteins • chemo-
therapy • membrane transport
 
Introduction
 
Multidrug resistance (MDR)
 
1
 
 is the major obstacle to the
successful chemotherapeutic treatment of human cancers
(Simon and Schindler, 1994; Ling, 1997). Often a cancer
becomes resistant to many drugs of diverse structures and
mechanisms after exposure to only a few drugs (Biedler
et al., 1975; Bech-Hansen et al., 1976); it is then said to
have developed multidrug resistance. Such MDR cancers
often overexpress P-glycoprotein (Pgp), an ATP-binding
cassette (ABC) protein encoded by the 
 
MDR1
 
 gene
(Kartner et al., 1983; for a review, see Gottesman and
Pastan, 1993; Stein, 1997; Wadkins and Roepe, 1997; Ey-
tan and Kuchel, 1999). These cells are characterized by the
decreased accumulation of many classes of drugs, com-
monly called MDR drugs. The accumulation of MDR
drugs in these cells is enhanced by other compounds
known as MDR reversers.
Most studies of MDR have used drug-resistant cells gen-
erated by selection with chemotherapeutic drugs. These
drugs are highly mutagenic and tumor cells are genetically
unstable. Thus this selection process leads to a host of
changes in cellular physiology that may result in drug re-
sistance. Among them: decreased susceptibility to apopto-
sis (Robinson et al., 1997), increased DNA repair and drug
metabolism (Deffie et al., 1988); increased cellular pH
(Thiebaut et al., 1990; Roepe et al., 1993; Simon et al.,
1994); decreased lysosomal and endosomal pH (Schindler
et al., 1996; Altan et al., 1998); decreased plasma mem-
brane potential (Roepe et al., 1993); increased plasma
membrane conductance to chloride (Gill et al., 1992) and
ATP (Abraham et al., 1993); and increased rates of vesicle
transport (Altan et al., 1999). Studying a subclone after se-
lection in chemotherapeutics has made it difficult to deter-
mine the degree to which Pgp contributes to MDR in any
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particular drug-selected cell line. It has also complicated
studying Pgp’s underlying mechanism. The most accepted
mechanism is that Pgp is an ATP-dependent drug efflux
pump. Alternatively, it has been proposed that Pgp raises
the cytosolic pH and lowers the plasma membrane poten-
tial, thereby decreasing the accumulation of weak bases
and positively charged drugs into the cytosol (Hoffman et
al., 1996).
To elucidate the mechanism of Pgp, we used a novel
technique of in situ biochemistry. We transiently ex-
pressed a fusion protein between Pgp and green fluores-
cent protein (GFP) to produce a mixed population of cells
with a broad range of expression levels. Fluorescence was
used to quantify simultaneously the expression and the ac-
tivity of Pgp in individual cells. This eliminates the con-
founding aspects of drug selection or even clonal expan-
sion. Expression of Pgp in the absence of drug selection
was shown to be sufficient to produce drug resistance to a
spectrum of unrelated chemotherapeutic drugs. The re-
sulting quantification of the relation between Pgp expres-
sion and activity is consistent with the concept of Pgp as an
active efflux pump and not consistent with cooperativity
between either Pgp, substrate or inhibitor molecules. Fi-
nally, our study demonstrates the advantages of using in
situ assays for quantitative biochemistry.
 
Materials and Methods
 
Cell Culture
 
HeLa cells (ATCC CCL-2) were cultured as per ATCC recommenda-
tions. MCF-7/ADR cells were cultured as described (Altan et al., 1998).
 
Construction and Expression of Vector
 
All restriction enzymes and T4 DNA ligase were from New England Bio-
labs. pGEM3Zf(
 
2
 
)Xba-MDR1.1, a phagemid containing the human
 
MDR1
 
 cDNA, was purchased from ATCC. To make the PgpGFP fusion
vector, site-directed mutagenesis using the UNG-DUT method (Kunkel,
1985) was performed to eliminate the 3
 
9
 
 stop codon and introduce a SalI
site. The Pgp open reading frame was excised using XbaI on the 5
 
9
 
 end
and SalI on the 3
 
9
 
 end and inserted into pEGFP-N1 (Clontech) cut with
the NheI and SalI. PgpCFP was subsequently constructed by replacing the
EGFP with ECFP from pECFP (Clontech). Transfections used Fugene 6
reagent (Roche Molecular Biomedical).
 
Fluorescent Microscopy
 
Epifluorescence microscopy was done on an inverted IX-70 microscope
(Olympus America). The image was collected using the Orca cooled CCD
camera (Hamamatsu Photonics), an IMAQ-1424 digital image acquisition
card and in-house software written in LabVIEW (National Instruments).
Excitation was provided using a 150 Watt Xenon arc lamp (OptiQuip).
Excitation and emission filters were selected using filter wheels (Ludl
Electronic Products). All filters were from Chroma. The following excita-
tion and emission filters were used for epi-fluorescent microscopy: CFP:
 
l
 
ex
 
 
 
5 
 
400–430 nm, 
 
l
 
em
 
 
 
5 
 
460–500 nm; GFP, BCECF, calcein, SNAFL-1,
and SNAFL calcein: 
 
l
 
ex
 
 
 
5 
 
480–490 nm, 
 
l
 
em
 
 
 
5 
 
500–550 nm; Hoechst 342
and FURA-2: 
 
l
 
ex
 
 
 
5 
 
340–380 nm, 
 
l
 
em
 
 
 
5 
 
430–470 nm; tetramethyl-
rhodamine methyl ester, SNARF-1, and SNARF calcein: 
 
l
 
ex
 
 
 
5 
 
530–560 nm,
 
l
 
em
 
 
 
5 
 
570–650 nm.
Confocal microscopy was done on an upright Axiplan 2 microscope
with a LSM 510 confocal attachment (Carl Zeiss). Excitation was pro-
vided by an Argon/Krypton laser with lines at 488 and 568 nm and a He-
lium/Neon laser at 633 nm. The following laser lines and emission filters
were used for confocal microscopy: GFP: 
 
l
 
ex
 
 
 
5 
 
488 nm, 
 
l
 
em
 
 
 
5 
 
500–530 nm;
Texas Red, Cy3, and TMRE: 
 
l
 
ex
 
 
 
5 
 
568 nm, 
 
l
 
em
 
 
 
5 
 
580 nm; LP, Fura Red,
and daunorubicin: 
 
l
 
ex
 
 
 
5 
 
488 nm, 
 
l
 
em
 
 
 
5 
 
580 nm LP.
 
Immunofluorescence
 
Cells were plated on 18-mm glass coverslips placed in 12-well dishes. For
Pgp surface staining, live cells were incubated with 1.22 
 
m
 
g/ml 4E3 (Da-
koA) or 2 
 
m
 
g/ml UIC2 (Immunotech), washed, stained with Texas red–
conjugated anti–mouse IgG antibody at 1:500 (Sigma), and fixed. For tu-
bulin staining, cells were incubated for 30 min in the presence of indicated
concentrations of vincristine (Calbiochem), colchicine (Calbiochem), or
nocodazole (Sigma). Cells were then fixed, permeabilized, and labeled
with 2 
 
m
 
g/ml Cy3-labeled anti-
 
b
 
-tubulin antibody, clone TUB 2.1 (Sigma).
 
Dual Labeling with Drugs and Dyes in Living Cells
 
All fluorescent dyes were from Molecular Probes. Daunorubicin was from
Calbiochem. Prior to observation, cells were incubated with the indicated
drug or dye for the indicated amount of time in Opti-MEM without phenol
red and with 10 mM Hepes (Life Technologies) in a 5% CO
 
2
 
, 37
 
8
 
C in-
cubator.
 
Ratiometric pH Imaging
 
SNARF-1 is a ratiometric pH indicator that emits at 640 nm in the basic
form and 580 nm in the acidic form. Cells were loaded with 1 
 
m
 
M SNARF-1
AM in Opti-MEM for 30 min and resuspended in dye-free Opti-MEM
before imaging. Three images were acquired for each field: GFP and
SNARF-1 acid: 
 
l
 
ex
 
 
 
5 
 
530–560 nm, 
 
l
 
em
 
 
 
5 
 
570–590 nm; and SNARF-1 base:
 
l
 
ex
 
 
 
5 
 
530–560 nm, 
 
l
 
em
 
 
 
5 
 
600–660 nm. Calibration was done as previously
described (Altan et al., 1998).
 
FACS
 
®
 
 Analysis
 
Cells were dissociated using Cell Stripper (Cellgro), incubated for 30 min
in Opti-MEM with 50 nM TMRE and analyzed using FACScan
 
®
 
 and
CellQuest software (Becton Dickinson). GFP and TMRE fluorescence
were acquired using FL1 (515–545 nm) and FL2 (564–606 nm), respec-
tively. To estimate the number of GFP from fluorescence, 6-
 
m
 
m SPHERO
yellow calibration particles (PharMingen) were used. The number of GFP
molecules per cell was estimated to be 1.5
 
3
 
 the FITC equivalent fluores-
cence units (Tsien, 1998).
 
Results
 
Effect of P-Glycoprotein GFP Fusion Protein 
Expression on Drug Accumulation
 
How much of the decreased accumulation of drugs and
fluorescent dyes can be attributed to Pgp expression
alone? Our approach was to transiently transfect cells with
a fusion of Pgp and green or cyan fluorescent protein. This
produced a diverse population of cells, ranging from those
that expressed large amounts of Pgp to those that failed to
express the protein at all. The activity of Pgp was then
quantified in individual cells that had been exposed to the
same treatments, but differed substantially in their levels
of Pgp. Two assays were used to examine the effects of the
Pgp-fluorescent protein on chemotherapeutic drugs. First,
we examined the cellular accumulation of structurally di-
vergent MDR fluorescent dyes including those that are
constitutively positively charged, weakly basic or un-
charged. Second, we measured the cellular activity of mi-
crotubule-disrupting chemotherapeutics by their effect on
microtubules. Thus the activity of Pgp was quantitatively
studied as a function of its levels of expression in individ-
ual cells.
To assure that a correctly folded, full-length fusion pro-
tein was produced in the transfected cells, we used immu-
noblotting and immunofluorescence. The PgpGFP fusion
protein was detected as an 
 
z
 
200-kD band by either an
anti-Pgp antibody (clone F4) or anti-GFP antibody. Wild- 
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type Pgp appeared as an 
 
z
 
170 kD band (data not shown).
Immunofluorescence of three epitope-specific anti-Pgp
antibodies (clones F4, 4E3, and UIC2) colocalized with
GFP fluorescence (data not shown).
 
Weak Base Chemotherapeutic Drugs
 
Daunorubicin is a weak base with one protonatable nitro-
gen at physiological pK
 
a
 
 (Altan et al., 1998). Cells express-
ing PgpGFP accumulated dramatically less daunorubicin
(Fig. 1 A). Note that in this field, there were three cells
that did not express Pgp (left), one that expressed a high
level of protein (bottom right), and one that produced a
small amount (top right, asterisk). The level of Pgp expres-
sion was inversely correlated with daunorubicin accumu-
lation. For example, the daunorubicin fluorescence was
 
.
 
100-fold lower in the cell that expressed a high level of
Pgp compared with its Pgp negative neighbor. Similarly,
the level of Pgp expression was inversely related to the cel-
lular accumulation of mitoxantrone, a clinically important
anthracenedione chemotherapeutic that is also a weak
base but that is significantly different in structure from
daunorubicin (data not shown). The MDR reversers vera-
pamil (40 
 
m
 
M, Fig. 1 A) and cyclosporin A (10 
 
m
 
M, data
not shown), completely reversed the effect of PgpGFP ex-
pression on accumulation of daunorubicin. The UIC2 anti-
Pgp antibody, at 10 
 
m
 
g/ml, partially reversed the effect of
PgpGFP expression (data not shown).
 
Positively Charged Dyes
 
We tested the effects of expressing PgpGFP on two MDR
compounds that have constitutive positive charges, the
DNA stain Hoechst 33342 (Ho342) and the mitochondrial
dye tetramethylrhodamine methyl ester (TMRE). (TMRE
is similar to the well known MDR dye rhodamine 123
whose fluorescence overlaps GFP.) In cells expressing
PgpGFP the TMRE fluorescence was virtually undetect-
able and the Ho342 fluorescence was threefold lower (Fig.
1 B), consistent with previous reports on the specificity of
Pgp (Lizard et al., 1995b). The accumulation of both
Ho324 and TMRE in the cells expressing PgpGFP was in-
creased by the MDR-reversers verapamil (40 
 
m
 
M) and cy-
closporin A (10 
 
m
 
M; data not shown). Staining with both
TMRE and Ho342 serves as a good control for cell fitness.
In unhealthy cells, the loss of mitochondrial membrane
potential limits accumulation of TMRE while the degrada-
tion of the membrane permits large amounts of Ho342 to
enter (Sun et al., 1992; Lizard et al., 1995a).
 
Acetoxymethyl Esters
 
The effects of PgpGFP expression was tested on a number
of uncharged acetoxymethyl (AM) esters implicated as
MDR substrates. AM esters of many hydrophilic indicator
dyes are used to facilitate cellular loading (Homolya et al.,
1993). Within the cell, esterases cleave AM groups, trap-
ping the dye inside the cell. Expression of PgpCFP or
PgpGFP substantially reduced the cellular accumulation
of several AM esters such as Fura Red (Fig. 1 C). Adding
verapamil (40 
 
m
 
M) increased Fura Red accumulation in
PgpGFP-expressing cells (data not shown). The effects of
PgpGFP on reducing the accumulation of BCECF, cal-
cein, and Fura-2 (Table I) correlate with the ability of each
 
AM ester dye to stimulate the ATPase activity of Pgp
(Homolya et al., 1993).
 
Microtubule-disrupting Drugs
 
We used a functional assay to quantify the effect of
PgpGFP expression on the cytosolic activity of chemo-
therapeutics. Certain chemotherapeutics, such as colchicine,
vincristine and nocodazole, depolymerize microtubules.
The state of a cell’s microtubules after being treated with
these drugs is a measurement of the cellular concentration
of the drug. Thus, we examined the microtubules using im-
munofluorescence against 
 
b
 
-tubulin after drug treatment.
Cells expressing PgpGFP maintained microtubules in
80 nM vincristine while nonexpressing cells in the same
field did not (Fig. 2 B). Cells expressing high levels of
PgpGFP had intact microtubules even in 2 
 
m
 
M vincristine
(Fig. 2 A). Thus, expression of PgpGFP correlates with a
 
.
 
25-fold decrease in vincristine accumulation. Expression
of PgpGFP also decreased the sensitivity of cells to colchi-
cine, but had no effect on sensitivity to nocodazole (Table II).
 
Expression Activity Profile of PgpGFP
 
Various mechanisms have been proposed to account for
the effects of Pgp on drug accumulation in the cell (Wad-
kins and Roepe, 1997; Stein, 1997; Eytan and Kuchel,
1999). Each has a different characteristic dependence of
drug accumulation on Pgp expression level. We used
FACS
 
®
 
 to quantify PgpGFP expression and TMRE accu-
mulation over a wide dynamic range. Approximately 50%
of HeLa cells expressed PgpGFP and the expression level
varied 
 
.
 
100-fold (Fig. 3 A). In cells expressing the highest
level of PgpGFP, the average TMRE accumulation was
100-fold less than in nonexpressing cells. A dot plot of
TMRE fluorescence versus GFP fluorescence shows an in-
verse linear relationship on a logarithmic scale with a
slope close to 
 
2
 
1, and a linear fit of slope 
 
2
 
1 is shown as
the solid line (Fig. 3 B). Hence, it appears that expression
of PgpGFP has an inverse linear relationship to TMRE ac-
cumulation. This relationship is consistent only with a
model in which Pgp mediates active efflux itself, without
cooperativity between either enzyme or substrate (see be-
low).
For an idealized cell with a plasma membrane efflux
pump, where a single substrates interacts with a single en-
zyme, the steady-state ratio of cellular drug concentration
(
 
D
 
in
 
) to external concentration (
 
D
 
out
 
) follows the follow-
ing equation: 
 
D
 
in
 
/D
 
out
 
<
 
1/(1 
 
1
 
 
 
X
 
), where 
 
X 
 
5 
 
N
 
 ·
 
 C/(K
 
m
 
 
 
·
 
P
 
 ·
 
 S)
 
 (see Appendix). Here, 
 
N
 
 is the number of pumps, 
 
C
 
Table I. The Effect of PgpGFP or PgpCFP Expression on 
Accumulation of AM Esters
 
Dye Effects on fluorescence
 
BCECF AM (CFP) 3–10-fold
Calcein AM (CFP)
 
.
 
10-fold
Fura-2 AM (GFP)
 
.
 
10-fold
Fura Red AM (GFP)
 
.
 
10-fold
SNAFL-1 diacetate (CFP)
 
.
 
10-fold
SNAFL calcein AM (CFP)
 
.
 
10-fold
SNARF-1 AM (GFP)
 
.
 
10-fold
SNARF calcein AM (GFP)
 
.
 
3-fold 
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is the catalytic constant,
 
 P 
 
is the drug permeability and 
 
S 
 
is
the plasma membrane surface area. When 
 
X
 
 is 
 
,
 
1, the cel-
lular drug concentration approaches the external drug
concentration and increasing 
 
X
 
 has little effect. When 
 
X
 
 is
 
.
 
1, the ratio approaches 
 
1/X
 
, an inversely linear relation-
ship. We modeled this equation using the following approxi-
mate constants:
 
 P 
 
5 
 
10
 
2
 
5
 
 cm/s, 
 
S 
 
5 5,000 mm2, Km 5 10
mM. Fig. 3 H shows a plot Din/Dout as a function of the
number of pump molecules per cell. The five plots, from
left to right, assume catalytic constants of 10, 1, 0.1, 0.01,
and 0.001 drug molecules pumped per Pgp per second.
The model predicts that an inhibitor should shift the
TMRE accumulation to PgpGFP relationship to the right,
analogous to decreasing the catalytic constant in Fig. 3 H.
Figure 1. Effect of PgpGFP expression on the accumulation of fluorescent dyes. (A) PgpGFP-transfected HeLa cells were incubated
for 30 min with 1 mM daunorubicin without (top) or with (bottom) 40 mg/ml verapamil. GFP and daunorubicin fluorescence were im-
aged using a confocal microscope. The fluorescence profile along the line drawn in the merge image was quantified (right). (B) Cells
were incubated for 30 min with 200 nM TMRE and 200 nM Ho342, and the fluorescence images of GFP, TMRE, and Ho342 were ac-
quired using an epifluorescence microscope. (C) Cells were incubated for 30 min with 5 mM Fura Red AM and GFP and Fura Red flu-
orescence were imaged on a confocal microscope. Bars, 20 mm.Chen and Simon Mechanism of P-Glycoprotein 867
This was tested by coincubating cells with TMRE and 3.13,
6.25, 12.5, 25, or 50 mM verapamil (Figs. 3, C–G, respec-
tively). The solid lines on these figures is the fit from Fig. 3
B as a reference. Indeed, as the concentration of vera-
pamil increased, the curve shifted right. To quantify the ef-
fect of verapamil, we estimated the average TMRE fluo-
rescence of cells showing GFP fluorescence of 103 at
different verapamil concentrations using the dash lines in
Figs. 3, B–G. The plot of TMRE fluorescence versus vera-
pamil concentration shows an approximate linear relation-
ship (Fig. 3 I), as expected from a specific inhibitor and
lack of cooperativity between inhibitor molecules (see Ap-
pendix). Our data estimate the Ki of verapamil to be 3 mM,
in full agreement with published data (Lan et al., 1996).
Thus, the FACS® data shows that Pgp mediates active
drug efflux, and that verapamil is a specific inhibitor.
Effect of PgpGFP Expression on Cellular pH
MDR cells have been shown to have higher cytosolic pH
(Keizer and Joenje, 1989; Simon et al., 1994). Since such
higher pH results in decreased concentration of weak base
drugs this could be the consequence of selection in chemo-
therapeutics rather than a specific effect of expressing Pgp.
However, stable transfection of Pgp has been reported to
raise cytosolic pH (Thiebaut et al., 1990) even without
chemotherapeutic drug selection (Hoffman et al., 1996).
We examined the effect of PgpGFP expression on cyto-
solic pH using SNARF-1. Fig. 4, A–F, show calibration at
three different pH. As expected, the ratio increased with
increasing pH in an exponential manner. PgpGFP expres-
sion did not affect the ratio of the calibration images. Mea-
surement of cellular pH of cells in medium showed that
both PgpGFP expressing and nonexpressing cells had a cy-
tosolic pH of z7.2 (Fig. 4, G and H). Thus, Pgp expression
has no effect on cellular pH.
Discussion
The goal of our study was to determine if Pgp expression
in the absence of any selection was sufficient to produce
multidrug resistance and, if so, to understand the mecha-
nism of Pgp. To this end, we devised a technique that al-
Figure 2. Effect of PgpGFP expression on vincristine-mediated microtubule depolymerization. PgpGFP-transfected HeLa cells were
incubated with 2 mM or 80 nM vincristine for 30 min and stained with a Cy3-conjugated anti-b-tubulin antibody. Arrows indicate
PgpGFP expressing cells and arrowheads indicate nonexpressing cells. Bars, 20 mm.
Table II. The Effect of High Level PgpGFP Expression on 
Drug-mediated Microtubule Depolymerization
Drug Fold resistance
Colchicine 5–25-fold
Nocodazole None
Vincristine 25–125-foldThe Journal of Cell Biology, Volume 148, 2000 868
lowed the levels of Pgp expression to be directly compared
with cellular accumulation of chemotherapeutics. We de-
signed a novel method that took advantage of GFP, a pro-
tein that has revolutionized cell biology by permitting the
study of localization and movement of proteins in living
cells. We extended the range of application of GFP to the
study of biochemical processes in living cells. Tradition-
ally, enzymes are studied in vitro, away from their natural
cellular environment. Enzyme analysis in living cells is
hampered by two constraints. First, intracellular enzyme
concentration usually varies within a narrow range, and
second, enzyme concentration and intracellular localiza-
tion cannot be easily measured. The use of transient trans-
fection addresses the first problem since it generates a
large range of expression levels. Using GFP fusion pro-
teins addresses the second problem. A previous approach
to in vivo enzyme analysis also employed transient trans-
fection of the enzyme. In that study, enzyme activity was
detected with a fluorescent substrate. The amount of en-
zyme was measured by subsequent immunoquantification
(Morita et al., 1995). Using a GFP fusion protein allowed
us to measure simultaneously the quantity, localization
and kinetic activity of an enzyme in living cells.
Expression of PgpGFP resulted in dramatically de-
creased accumulation of many diverse compounds, includ-
ing the noncharged AM-esters, the weak base drug dauno-
rubicin, and the constitutively charged dyes TMRE and
Ho342. Decreased accumulation was also inferred from
the decreased sensitivities to microtubule depolymerizing
drugs vincristine and colchicine. This effect of PgpGFP ex-
pression was inhibited by an antibody against Pgp and
MDR reversers.
FACS® analysis showed that PgpGFP expression and
TMRE accumulation had an inverse linear relationship,
implying that PgpGFP mediates active efflux. Further-
more, this data implies that the TMRE extrusion is a bi-
molecular reaction: a single molecule of TMRE is pumped
at a time and a single Pgp unit (monomer or stable multi-
mer) is the catalytic unit. FACS® analysis further showed
that the concentration of verapamil and level of TMRE
Figure 3. FACS® analysis of
TMRE accumulation as a
function of PgpGFP expres-
sion. (A) Histogram of GFP
fluorescence of HeLa cells
transfected with PgpGFP.
Approximately 50% of the
cells were nonexpressing
showing a single peak of
z5 3 100 units. Transfected
cells showed a .100-fold
range of GFP fluorescence.
(B) Dot plot of transfected
cells incubated for 30 min
with 50 nM TMRE. The solid
diagonal line of slope 21 was
fit to the data. To estimate
the average TMRE fluores-
cence exhibited by cells with
GFP fluorescence of 103
units, a dashed line was drawn
from the center of cell den-
sity at 103 down and across to
the x and y axes. At all levels
of PgpGFP expression, there
were some cells that showed
TMRE fluorescence of 102
on the y-axis (marked as a
horizontal oval). Coincuba-
tion with propidium iodide
selectively increased the flu-
orescence of these cells, indi-
cating that they were most
likely dead (data not shown).
(C–G) Dot plot of cells coin-
cubated with the indicated
verapamil concentration. The
solid diagonal line was repro-
duced from B for reference. The average TMRE fluorescence exhibited by cells with GFP fluorescence of 103 units was estimated as in
B. (H) The ratio of drug in/drug out was modeled is described in text. Plots of Din/Dout as a function of number of Pgp per cell are shown
for five different catalytic constants of 10, 1, 0.1, 0.01, and 0.001 drug molecules per pump per second. (I) Plot of average TMRE fluores-
cence of cells exhibiting GFP fluorescence of 103 as a function of verapamil concentration from the dash lines drawn in B–G. Open cir-
cle indicates no verapamil control (not 1 mm).Chen and Simon Mechanism of P-Glycoprotein 869
accumulation in PgpGFP expressing cells were linearly re-
lated, suggesting that verapamil is an inhibitor and that
there is no interaction between pairs of verapamil mole-
cules.
Tumor cells are known to be genetically unstable and
that exposure to mutagenic compounds invariably results
in many mechanisms of drug resistance. Which combina-
tions of these mechanisms are clinically relevant has yet to
be established. The use of GFP fusions permits the study
of any one individual protein independently from other
drug resistance phenomena.
Appendix
We use the pump/leak model (Stein, 1997; Eytan and
Kuchel, 1999). The drug influx rate is the leak in and the
drug efflux rate is the leak out plus the pump rate out:
where the constants are defined in the text. To further sim-
plify our analysis, we assume that Din is small compared
with Km, which is safe since we used a TMRE concentra-
Influx P S Dout and ×× =
Efflux P S Din NCD in Din Km + () ¤ ×× + ×× =,
tion of 50 nM. The pump rate then approximates N · C ·
Din/Km.  The equilibrium concentration must satisfy the
equation  Influx 5 Efflux, giving
A noncompetitive inhibitor decreases the apparent C
according to the following formula:
where I is the inhibitor concentration. Thus, the apparent
C is halved when I 5 Ki. When I .. Ki, Capp approaches
an inverse linear relationship with I. For a competitive in-
hibitor, the apparent Km is increased such that
and the same analysis shows that when I 5 Ki, Kmapp is
doubled and Kmapp is linearly related to I when I .. Ki.
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